Literature DB >> 10779139

Neuropsychological follow-up in early-treated congenital hypothyroidism: a problem-oriented approach.

S Bargagna1, G Canepa, C Costagli, D Dinetti, M Marcheschi, S Millepiedi, L Montanelli, A Pinchera, L Chiovato.   

Abstract

Screening programs for congenital hypothyroidism (CH) dramatically improved the neuropsychological prognosis in affected children. However, mild impairments in cognitive performances, poorer motor skills, defective language abilities, and learning problems have been reported in some studies of early-treated CH children. The occurrence of these defects makes neuropsychological follow-up mandatory. The aim of the present study was to identify those neuropsychological functions that are more frequently affected in early-treated CH children and that might require prompt rehabilitation treatment to prevent permanent defects. The study group involved 24 CH children. Levothyroxine (LT4) treatment (initial dose 8-10 microg/kg per day) was started at mean age of 28 days (range 15-45) and was then adjusted with the goal to keep thyrotropin (TSH) and free thyroid hormone levels in the normal range. Cognitive evaluation was performed at 3, 5, and 7 years of age and did not significantly differ from that of controls. Mean neurological scores were lower in children 5 years of age than in controls. Children with severe neonatal hypothyroidism (serum thyroxine [T4] < 2 microg/dL) had significantly lower neurological scores compared to less affected CH children and normal controls. The most affected functions were balance, extremity coordination, fine motricity, quality of movements, associated movements, and head movements. Language disorders were observed in half of CH children at 3 and 5 years of age, but moderately severe defects were restricted to those with severe neonatal hypothyroidism. In conclusion, a problem-oriented, simplified neuropsychological follow-up of early-treated children with CH should not systematically include the frequent repetition of time-consuming and expensive psychometric tests because individual IQ scores are in the normal range of tests in almost all CH children and can be differentiated from those of normal controls only on a population-statistic basis. Selected tests of motor proficiency are indicated at 3 and 5 years of age to detect those defects in motor skills that appear to be more specifically affected in CH children. Language performances are at particular risk in CH children, and should be always checked at 3 and 5 years of age. Children with even mild language disorders or delayed language achievements should be regularly reevaluated at 6-month intervals and, if no spontaneous improvement is observed, they should receive specific rehabilitation treatment. No further motor and language evaluation is warranted in CH children with normal tests at age 5 years.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10779139     DOI: 10.1089/thy.2000.10.243

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  11 in total

Review 1.  Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment.

Authors:  L Bartalena; F Bogazzi; L E Braverman; E Martino
Journal:  J Endocrinol Invest       Date:  2001-02       Impact factor: 4.256

Review 2.  Iodine status and supplementation in pregnancy: an overview of the evidence provided by meta-analyses.

Authors:  Laura Croce; Luca Chiovato; Massimo Tonacchera; Elena Petrosino; Maria Laura Tanda; Mariacarla Moleti; Flavia Magri; Antonella Olivieri; Elizabeth N Pearce; Mario Rotondi
Journal:  Rev Endocr Metab Disord       Date:  2022-10-13       Impact factor: 9.306

3.  Hearing impairment in congenitally hypothyroid patients.

Authors:  Mahin Hashemipour; Silva Hovsepian; Mostafa Hashemi; Massoud Amini; Roya Kelishadi; Somaye Sadeghi
Journal:  Iran J Pediatr       Date:  2012-03       Impact factor: 0.364

Review 4.  Congenital hypothyroidism: a review of current diagnostic and treatment practices in relation to neuropsychologic outcome.

Authors:  Joanne Rovet; Denis Daneman
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.930

5.  Outcome of congenitally hypothyroid screening program in isfahan: iran from prevention to treatment.

Authors:  Mahin Hashemipour; Elham Hashemi Dehkordi; Silva Hovsepian; Massoud Amini; Leila Hosseiny
Journal:  Int J Prev Med       Date:  2010

6.  Cognitive outcomes for congenital hypothyroid and healthy children: a comparative study.

Authors:  Mahtab Ordooei; Hadi Mottaghipisheh; Razieh Fallah; Azar Rabiee
Journal:  Iran J Child Neurol       Date:  2014

7.  Effect of Atomoxetine on the Cognitive Functions in Treatment of Attention Deficit Hyperactivity Disorder in Children with Congenital Hypothyroidism: A Pilot Study.

Authors:  Rongwang Yang; Weijia Gao; Rong Li; Zhengyan Zhao
Journal:  Int J Neuropsychopharmacol       Date:  2015-04-19       Impact factor: 5.176

8.  Intelligence quotient in children with congenital hypothyroidism: The effect of diagnostic and treatment variables.

Authors:  Seyed Badredin Najmi; Mahin Hashemipour; Mohammad Reza Maracy; Silva Hovsepian; Mahmood Ghasemi
Journal:  J Res Med Sci       Date:  2013-05       Impact factor: 1.852

Review 9.  Neuropsychological Alterations in Patients with Congenital Hypothyroidism Treated with Levothyroxine: Linked Factors and Thyroid Hormone Hyposensitivity.

Authors:  Karla Cristina Razón-Hernández; Norma Osnaya-Brizuela; Armando Valenzuela-Peraza; Esperanza Ontiveros-Mendoza; Luis Miguel Rodríguez-Serrano; Jorge Pacheco-Rosado; Gerardo Barragán-Mejía; Karla Sánchez-Huerta
Journal:  J Clin Med       Date:  2022-06-15       Impact factor: 4.964

10.  CONGENITAL HYPOTHYROIDISM AS A RISK FACTOR FOR CENTRAL HEARING PROCESS DISORDERS.

Authors:  Caio Leônidas Oliveira de Andrade; Aline Cupertino Lemos; Gabriela Carvalho Machado; Luciene da Cruz Fernandes; Lais Luz Silva; Hélida Braga de Oliveira; Helton Estrela Ramos; Crésio Aragão Dantas Alves
Journal:  Rev Paul Pediatr       Date:  2018-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.